What Happens When You Stop Semaglutide Or Tirzepatide
Before starting semaglutide or tirzepatide, it's fair to ask whether you'll have to stay on it. The best evidence comes from trials that took people off the medicine on purpose and tracked what happened next.
What Happened When Semaglutide Stopped
The STEP 4 trial (JAMA, 2021) started adults on weekly semaglutide. The 803 who reached the full 2.4 mg dose, the Wegovy dose, had lost an average of 10.6% of their body weight by week 20. They were then randomly assigned to keep taking it or switch to a placebo for 48 more weeks, with lifestyle counseling continuing in both groups. Those who stayed on lost another 7.9% of their body weight. Those switched to placebo regained 6.9%.
The STEP 1 trial extension (Diabetes, Obesity and Metabolism, 2022) looked at what happens when everything stops. People who had lost an average of 17.3% over 68 weeks came off both the medicine and the lifestyle program. A year later, they had regained about two-thirds of the weight they lost, leaving them 5.6% below where they started.
Tirzepatide Showed The Same Pattern
In SURMOUNT-4 (JAMA, 2024), 670 adults who had lost an average of 20.9% over 36 weeks on tirzepatide were split into two groups. Over the next 52 weeks, the group switched to placebo regained 14% of their body weight, while the group that stayed on lost another 5.5%. By the end, 89.5% of those who continued had kept at least 80% of their earlier loss, compared with 16.6% of those on placebo. Most people in these trials were women (79% in STEP 4 and 71% in SURMOUNT-4), and the figures are averages, so individual results vary.
It's Not Just The Scale
In the STEP 1 extension, most of the heart and metabolic improvements seen on semaglutide drifted back toward where they started during the year off treatment. The researchers concluded that ongoing treatment appears necessary to keep the improvements in weight and health. Put simply, these medicines work while you take them.
What That Means Before You Start
Plan for the long term, both for your expectations and for your budget. If you're thinking about stopping, talk with your provider first instead of quitting on your own, and do the same before restarting after a break rather than going straight back to your old dose. Our guide to keeping muscle on a GLP-1 covers habits worth building while you're on treatment.
Brand-Name And Compounded Versions
These trials studied semaglutide 2.4 mg and tirzepatide at 10 or 15 mg. Our guide to Ozempic vs. Wegovy and Mounjaro vs. Zepbound explains the brand names. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA has not evaluated them for safety or effectiveness, so the trial results can't be assumed to carry over to them. Wegovy and Zepbound both carry a boxed warning about thyroid C-cell tumors seen in rodents and shouldn't be used by anyone with a personal or family history of medullary thyroid cancer or MEN 2, and their labels also warn about pancreatitis and gallbladder problems. Get care quickly for severe stomach pain that won't go away, a lump or swelling in your neck, or trouble swallowing.
Where To Start
A licensed provider reviews your history, current medications, and goals, and decides whether a GLP-1 fits and what a realistic plan looks like. Bring up cost and how long you expect to stay on it at the first visit, since the trials show results depend on staying on treatment.
This guide explains general information and is not medical advice. It doesn't replace a licensed provider reviewing your own history.